Aerovate Therapeutics's total assets for Q3 2024 were $90.96M, a decrease of -18.56% from the previous quarter. AVTE total liabilities were $10.47M for the fiscal quarter, a -39.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.